🇺🇸 FDA
Patent

US 11690829

Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

granted A61KA61K31/343A61K31/4045

Quick answer

US patent 11690829 (Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder) held by OVID THERAPEUTICS INC. expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OVID THERAPEUTICS INC.
Grant date
Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/343, A61K31/4045, A61K31/437, A61P